<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02470117</url>
  </required_header>
  <id_info>
    <org_study_id>567/57</org_study_id>
    <nct_id>NCT02470117</nct_id>
  </id_info>
  <brief_title>Alginate-based Reflux Suppressant and Magnesium-aluminium Antacid Gel for Treatment of Heartburn in Pregnancy</brief_title>
  <official_title>Comparison of the Efficacy of Alginate-based Reflux Suppressant and Magnesium-aluminium Antacid Gel for Treatment of Heartburn in Pregnancy : A Randomized Double-Blind Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of alginate-based reflux suppressant and
      magnesium-aluminium antacid gel for treatment of heartburn in pregnancy. Half of the
      participants will receive alginate-based reflux suppressant, while the other half will
      receive magnesium-aluminium antacid gel.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of heartburn as measured by diary chart</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intensity of hearburn as measured by visual analog scale</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>satisfaction as measured by questionnaire</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life as measured by questionnaire SF-8</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with side effects</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fetal outcomes as measured by birth weight and Apgar scores</measure>
    <time_frame>at birth</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Heartburn in Pregnancy</condition>
  <arm_group>
    <arm_group_label>Alginate-based reflux suppressant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alginate-based reflux suppressant 15 ml oral every 6 hours for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>magnesium-aluminium antacid gel</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>magnesium-aluminium antacid gel 15 ml oral every 6 hours for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alginate-based reflux suppressant</intervention_name>
    <arm_group_label>Alginate-based reflux suppressant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>magnesium-aluminium antacid gel</intervention_name>
    <arm_group_label>magnesium-aluminium antacid gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women gestational age less than 36 weeks with heartburn

        Exclusion Criteria:

          -  Having medical disease that contraindicated to use study drug

          -  Allergic to alginate-based reflux suppressant and magnesium-aluminium antacid gel
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vorapong Phupong, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Chulalongkorn University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vorapong Phupong</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Hampson FC, Farndale A, Strugala V, Sykes J, Jolliffe IG, Dettmar PW. Alginate rafts and their characterisation. Int J Pharm. 2005 Apr 27;294(1-2):137-47.</citation>
    <PMID>15814238</PMID>
  </reference>
  <reference>
    <citation>Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013 Mar;108(3):308-28; quiz 329. doi: 10.1038/ajg.2012.444. Epub 2013 Feb 19. Erratum in: Am J Gastroenterol. 2013 Oct;108(10):1672.</citation>
    <PMID>23419381</PMID>
  </reference>
  <reference>
    <citation>Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006 Jul;131(1):283-311. Review.</citation>
    <PMID>16831611</PMID>
  </reference>
  <reference>
    <citation>Malmud LS, Charkes ND, Littlefield J, Reilley J, Stern H, Rosenberg R, Fisher RS. The mode of action alginic acid compound in the reduction of gastroesophageal reflux. J Nucl Med. 1979 Oct;20(10):1023-8.</citation>
    <PMID>231639</PMID>
  </reference>
  <reference>
    <citation>Richter JE. Review article: the management of heartburn in pregnancy. Aliment Pharmacol Ther. 2005 Nov 1;22(9):749-57. Review.</citation>
    <PMID>16225482</PMID>
  </reference>
  <results_reference>
    <citation>Quartarone G. Gastroesophageal reflux in pregnancy: a systematic review on the benefit of raft forming agents. Minerva Ginecol. 2013 Oct;65(5):541-9. Review.</citation>
    <PMID>24096290</PMID>
  </results_reference>
  <results_reference>
    <citation>Strugala V, Bassin J, Swales VS, Lindow SW, Dettmar PW, Thomas EC. Assessment of the Safety and Efficacy of a Raft-Forming Alginate Reflux Suppressant (Liquid Gaviscon) for the Treatment of Heartburn during Pregnancy. ISRN Obstet Gynecol. 2012;2012:481870. doi: 10.5402/2012/481870. Epub 2012 Nov 4.</citation>
    <PMID>23209926</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2015</study_first_posted>
  <last_update_submitted>July 26, 2016</last_update_submitted>
  <last_update_submitted_qc>July 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Vorapong Phupong</investigator_full_name>
    <investigator_title>Prof. Vorapong Phupong</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heartburn</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alginic acid</mesh_term>
    <mesh_term>Antacids</mesh_term>
    <mesh_term>Anti-Ulcer Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

